@entity460 and XXXX solubility in neonatal parenteral nutrient solutions containing @entity21931 .

@entity1 @entity4388 @entity462 @entity17500 @entity535 @entity5836 @entity1391 @entity10041 @entity460 @entity21931 @entity413 @entity8856
Factors affecting solubilities of @entity460 and @entity1391 in neonatal total parenteral nutrient (TPN) solutions containing a new @entity535 formulation were examined. Twelve TPN solutions containing various concentrations of @entity21931 , an @entity535 formulation specific for @entity1 and young @entity1 , were prepared in 10% @entity413 injection. Some of the solutions also contained @entity462 40 mg/g of protein and either @entity4388 or @entity5836 (lipid emulsion buffer) to buffer the solution pH to simulate that produced by simultaneously administering lipid emulsion through the i.v. line. @entity10041 and monobasic and dibasic @entity17500 were added to 20-mL samples of the TPN solutions to achieve @entity460 concentrations of 10, 20, 30, 40, or 50 meq/L with @entity1391 concentrations of either 10, 20, 30, or 40 mmol/L; a total of 20 samples of each @entity8856 solution was prepared. Samples were inspected visually for precipitation or crystallization after 18 hours at 25 degrees C and again after 30 minutes in a water bath at 37 degrees C. Clear samples at this time were also examined microscopically for evidence of microcrystallization. Solubility curves were prepared by plotting graphically the concentrations at which either visual or microscopic precipitation occurred. Temperature, @entity535 concentration, and the addition of @entity462 and lipid emulsion buffer each influenced the solubilities of @entity460 and @entity1391 in the TPN solutions. The use of @entity21931 as the @entity535 source allowed slightly greater concentrations of @entity1391 to be solubilized as compared with older @entity535 formulations.(ABSTRACT TRUNCATED AT 250 WORDS)
